$8.86
+0.23 (+2.67%)
Open$9.04
Previous Close$8.63
Day High$9.51
Day Low$8.20
52W High$10.00
52W Low$4.50
Volume—
Avg Volume78.7K
Market Cap192.70M
P/E Ratio—
EPS$-1.34
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+269.9% upside
Current
$8.86
$8.86
Target
$32.77
$32.77
$27.05
$32.77 avg
$46.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.57M | 16.36M | 16.49M |
| Net Income | -25,427,370 | -919,800 | -1,097,385 |
| Profit Margin | -202.2% | -5.6% | -6.7% |
| EBITDA | -27,850,267 | -1,433,447 | -1,263,705 |
| Free Cash Flow | — | -1,064,720 | -1,173,966 |
| Rev Growth | — | +3.8% | -10.0% |
| Debt/Equity | — | 1.22 | 1.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |